OneSource Specialty Pharma Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/omod5s5122tp0kpiksq8xt25.pdf

Key Takeaways


DDC Capacity: The Near-Term Growth Engine

Sharma: "And this is not just the filling capacity. I think that's what is important to highlight here and what really differentiates OneSource from every other CDMO is that every one of our lines are backed by full end-to-end capabilities, whether it is not only cartridge filling, but assembly, labeling, packaging and so on, including cold chain all under one roof. And this differentiates us not only in India, but even globally."

Semaglutide: Supply-Constrained, Not Demand-Constrained

Sharma: "This was a product which was always constrained by supply rather than the demand, whether it is the markets which are the largest in the world like U.S. and Europe, all these other markets which are now available off patent..."

Biologics: Building the Post-FY28 Story

Sharma: "These wins, whether the U.S. or Europe, these really reflect the integrated offering, which we have, which we call from gene to device in biologics, which again, very few CDMOs offer and the fact that India's growing position as a trusted hub of global biologics biosimilar development as well as manufacturing."

Base Business & Injectables Expansion


Margins, Costs & Operating Leverage

Sharma: "The very fact that when there is an increase in batch sizes in a sterile business, the cost of manufacturing per unit comes down, and we are happy to share the savings there with our customers. So it's a fairly win-win."

Working Capital & Balance Sheet

Bhagania: "I do believe that it is not structural. It is temporary, and it is only a timing impact. Hopefully, within a quarter or 2, we should start seeing this getting normalized."

Guidance & Commitments

CommitmentSpecificsTimeline
FY28 revenue and EBITDA$400 mn revenue, $160 mn EBITDAFY28
All 3 DDC lines fully operationalLines 1, 2 and 3 available for full-year contributionFY28
Line 3 commercializationQualification and commercial start; every effort being made for Q4 FY27Q4 FY27 or early FY28
Line 2 and Line 3 utilizationEach line to reach 225–230 sterile days per yearRapidly after qualification
Dr. Reddy's supply restartAPI supply commenced; first to Canada, then multiple other marketsWithin current quarter (Q3 FY27)
Dr. Reddy's additional market approvalsApprovals in additional markets beyond those already heldNext 2 quarters
Injectables new capacityPrefilled syringes and new lyophilization capacity availableQ3 FY27 onwards
Working capital normalizationShipping-related cycle-time impact of 45–60 days to reverseWithin 1–2 quarters
Effective tax rateCurrent ETR levels sustainedThrough at least Q3 FY28
Debt ceilingUnder 1.5x EBITDAThrough FY28
ROCE targetHigh 20sBy end of FY28

Key Metrics

MetricQ2 FY27
Revenue>₹500 cr, +37% YoY and +15% QoQ
EBITDA+53% YoY, +32% QoQ
EBITDA margin32%, expanded >400 bps QoQ
First-half EBITDA growth+47% YoY
FY28 revenue guidance$400 million, reaffirmed
FY28 EBITDA guidance$160 million, reaffirmed
DDC sterile production daysDoubled with Line 2 operational from September
Line 2 batch size capabilityUp to 750 liters; customers ramping to 500 liters
Line 1 output~50,000–55,000 pens/day at 200 liters
Line 2 output at 500 liters~120,000–130,000 pens/day
Steady-state DDC mix target75% commercial, 25% MSA per line
Softgel capacity utilization visibility80%+
India semaglutide monthly units>200,000 as of September, up from ~20,000–25,000 pre-patent expiry
Canada semaglutide market~1.6–1.7 crore units post-genericization, continuing to grow
Currency fluctuation impact~$350k, reported separately in financials
Debt level targetUnder 1.5x EBITDA
ROCE target by end of FY28High 20s